Matthew Galsky, MD, Icahn School of Medicine at Mount Sinai, and Karine Tawagi, MD, University of Illinois, detail the event-free survival subgroup analyses based on disease stage from the CREST study, which investigated sasanlimab in combination with BCG in BCG-naive, high-risk NMIBC.
This post hoc analysis adds further support for the potential of sasanlimab in combination with BCG as a practice-changing treatment in patients with aggressive disease.
This post hoc analysis adds further support for the potential of sasanlimab in combination with BCG as a practice-changing treatment in patients with aggressive disease.
- Category
- Oncology

Be the first to comment